Disease Areas
ALS is a progressive neurodegenerative disease that robs people of the ability to move and leads them to lose their ability to speak — and eventually breathe.1
For over a decade, Biogen has been committed to advancing ALS research to provide a deeper understanding of all forms of this devastating disease, which currently impacts an estimated 352,000 people worldwide.2,3*
By leveraging established scientific capabilities and embarking on strong R&D collaborations, we’re determined to follow the science to advance a comprehensive, multi-modality ALS portfolio that fosters our long-term leadership in this space.
Amyotrophic lateral sclerosis (ALS) is a fatal, adult-onset neurodegenerative disorder. Symptoms include progressive muscle weakness, paralysis and respiratory complications. Learn more about how the disease progresses in adults.
ALS impacts approximately 352,000 people worldwide. 2,3*
Average life expectancy for people with ALS is three to five years from the time of symptom onset.4
Two percent of ALS cases are caused by mutations in the SOD1 gene. Life expectancy in SOD1-ALS varies widely, with some patients surviving less than a year. 5